Only 10‒30% of patients with chronic myeloid leukemia (CML) achieve treatment-free remission (TFR) because the factors that determine successful discontinuation of tyrosine kinase inhibitors (TKIs), the current cornerstone of CML care, remain poorly understood. Mapping the optimal treatment pathway that gives the greatest chance of a successful TKI discontinuation attempt could help to make TFR a clinical reality for more patients.
Planned projects partners are: Karolinska Institutet, Swedish CML register (Sweden); South Australian Medical Research Institute (Australia); Bergonie Cancer centre Bordeaux - Bordeaux university - FiLMC french Group (France), Chang Gung Memorial Hospital - Nationwide TFR register(Taiwan), Fundaleu Hospital and Clinical Research Center Buenos Aires (Argentina), Hopital Saint-Louis APHP (France), Hospital Santa Marcelina (Brazil), Hospital Universitario de Gran Canaria Dr. Negrín (Spain), Imperial College London (UK), Instituto do Cancer do Estado de Sao Paulo (ICESP) (Brasil), Faculdade de Medicina da Universidade de Sao Paulo (USP)(Brasil), Italy Instituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" (Italy), Peking University People's Hospital (China), Princess Margaret Cancer Centre - University of Toronto (Canada), Singapore General Hospital/Duke-NUS Medical School (Singapore), South Australian Health and Medical Research Institute (South Australia), The Czech Leukemia Study Group for Life - nationwide collaboration (Czech Republic), Universitätsmedizin Mannheim der Universität Heidelberg - Deutsche CML Studiengruppe (Germany), Université Versailles Saint Quentin en Yveline - Centre Hospitalier de Versailles - French CML group (FiLMC) (France), Brazil University Hematology Center (Brazil), University of Liverpool (UK), Italy University of Turin - Italian TFR register (Italy).
This project will harness the HARMONY Big Data Platform, together with pooled data from multiple international collaborators within the International CML Foundation Treatment-Free Remission Alliance (iCMLf TFR Alliance), to explore the multiple factors that drive outcomes after TKI discontinuation.
The study will include a total cohort of over 2.000 CML patients and will focus on four specific aims:
As the HARMONY Big Data platform is the largest TFR CML register in Europe, it is hoped that this research will help bridge existing gaps in knowledge and pinpoint the optimal treatment pathway leading to TFR for patients with CML. This would allow for better guided clinical care of CML, helping more patients to successfully discontinue treatment and paving the way towards a possible cure.